EDWARD MIKULA: Open Payments
NPI 1639506165 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,071 in 93 payments from 21 companies in 2025. Trend: 2023 $2,482 · 2024 $2,592 · 2025 $2,071
Food & beverage: $2,071
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $242 |
| Novartis Pharmaceuticals Corporation | 12 | $223 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $205 |
| Amgen Inc. | 8 | $192 |
| E.R. Squibb & Sons, L.L.C. | 8 | $142 |
| Alnylam Pharmaceuticals Inc. | 5 | $141 |
| Abbott Laboratories | 1 | $135 |
| SCPHARMACEUTICALS INC. | 6 | $106 |
| Boston Scientific Corporation | 3 | $95 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 6 | $93 |
Products named: LEQVIO, ELIQUIS, JARDIANCE, REPATHA, AMVUTTRA, JOT DX, FUROSCIX, WATCHMAN FLX.
Industry payments across MD — which companies pay providers there.
